biostudies-literatureUnknown74(1)Reina-Couto MUniversidade do Porto<h4>Background and aims</h4>Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment.<h4>Material and methods</h4>Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single Inflammation research : official journal of the European Histamine Research Society ... [et al.]26https://www.ebi.ac.uk/biostudies/studies/S-EPMC11762693biostudies-literatureEndocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.PMC11762693Pereira-Terra PSarmento APaiva JADias CCSilva-Pereira CSousa TMartins SAlbino-Teixeira AGuimaraes JTRoncon-Albuquerque RReina-Couto MAlves DTavares MBessa JTeixeira-Santos LMorato MPinho DfalseEndocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.<h4>Background and aims</h4>Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment.<h4>Material and methods</h4>Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single 2025-01-01T00:00:00Z2025 Jan2026-06-12T05:15:55.921Z2025-04-03T23:22:38.405ZS-EPMC117626933986231110.1007/s00011-024-01964-8